Andrew McConaghie

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest from Andrew McConaghie

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.